Arts, Entertainment, Culture • Celebrities & Public Figures
"Project Northmoor" – Lord of the Rings actor start crowdfunding to buy J.R.R. Tolkien's home
"Project Northmoor" – Lord of the Rings actor start crowdfunding to buy J.R.R. Tolkien's home
Credit: via Project Northmoor

"Project Northmoor" is aiming to raise $6.1 million via crowdfunding to purchase J.R.R. Tolkien's home in Oxford, England, which soon will be on the market and transform it into a literary center in his honor. The campaign is led by author Julia Golding and will start on December 2.

Various actors, who starred in Lord of the Rings and The Hobbits, have joined a fellowship to save 20 Northmoor Road, including Ian McKellen, Martin Freeman and John Rhys-Davies.

"With the support of volunteers in the U.S., Golding has seized on this once-in-a-generation opportunity and negotiated a 3-month fundraising window with the current owner," Project Northmoor's statement reads.

AstraZeneca's Covid-19 vaccine averages 70% efficacy
AstraZeneca's Covid-19 vaccine averages 70% efficacy
Credit: D Wells / via Wikimedia Commons (Creative Commons Attribution ShareAlike 4.0)

Pharmaceutical giant AstraZeneca announced Monday that its Covid-19 vaccine has shown an average efficacy of 70% in large-scale trials. When given as a half dose followed by a full dose a month later, it showed 90% efficacy and with two full doses given a month apart, it showed 62% efficacy.

"What we've always tried to do with a vaccine is fool the immune system into thinking that there's a dangerous infection there that it needs to respond to -- but doing it in a very safe way. So we get the immune response and we get the immune memory ... waiting and ready if the pathogen itself is then encountered," so Professor Andrew Pollard, the trial's lead investigator at Oxford.

Regional News • Europe
AstraZeneca agrees to supply Europe Union members with 400 million doses of Covid-19 vaccine
AstraZeneca Manufacturing
AstraZeneca Manufacturing Credit: AstraZeneca

Europe’s Inclusive Vaccines Alliance (IVA), a group formed by the Netherlands, Germany, France and Italy, concluded a contract with AstraZeneca to provide 400 million doses of a possible vaccine developed by the University of Oxford. If the trial results convince regulators the vaccine is safe and effective, deliveries are expected to start by the end of 2020.

The company reached similar agreements with the United Kingdom and with the United States.